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D8+ T cell avidity
ucosal/systemic immunity
gG1 and IgG2a
a  b  s  t r  a  c  t
We have  established  that  the  efﬁcacy  of a heterologous  poxvirus  vectored  HIV vaccine,  fowlpox  virus
(FPV)-HIV  gag/pol  prime  followed  by attenuated  vaccinia  virus  (VV)-HIV  gag/pol  booster  immunisation,
is  strongly  inﬂuenced  by the  cytokine  milieu  at the  priming  vaccination  site,  with  endogenous  IL-13 detri-
mental  to  the  quality  of  the  HIV speciﬁc  CD8+  T cell  response  induced.  We  have  now  developed  a novel
HIV  vaccine  that co-expresses  a C-terminal  deletion  mutant  of  the  mouse  IL-4,  deleted  for  the essential
tyrosine  (Y119)  required  for  signalling.  In  our  vaccine  system,  the  mutant  IL-4C118  can  bind  to IL-4  type
I  and  II receptors  with  high  afﬁnity,  and  transiently  prevent  the  signalling  of  both  IL-4  and  IL-13  at the
vaccination  site.  When  this  IL-4C118  adjuvanted  vaccine  was  used  in an  intranasal  rFPV/intramuscular
rVV  prime-boost  immunisation  strategy,  greatly  enhanced  mucosal/systemic  HIV  speciﬁc  CD8+  T cells
with higher  functional  avidity,  expressing  IFN-,  TNF-  and  IL-2 and  greater  protective  efﬁcacy  were
detected.  Surprisingly,  the  IL-4C118  adjuvanted  vaccines  also  induced  robust  long-lived  HIV  gag-speciﬁc
serum antibody  responses,  speciﬁcally  IgG1  and  IgG2a.  The  p55-gag  IgG2a  responses  induced  were  of
a higher  magnitude  relative  to  the  IL-13R2  adjuvant  vaccine.  More  interestingly,  our recently  tested
IL-13R2  adjuvanted  vaccine  which  only  inhibited  IL-13  activity,  even  though  induced  excellent  high
avidity  HIV-speciﬁc  CD8+  T cells,  had  a detrimental  impact  on  the  induction  of gag-speciﬁc  IgG2a anti-
body  immunity.  Our  observations  suggest  that  (i)  IL-4  cell-signalling  in the  absence  of IL-13  retarded
gag-speciﬁc  antibody  isotype  class  switching,  or  (ii)  IL-13R2  signalling  was  involved  in  inducing  good
gag-speciﬁc  B  cell  immunity.  Thus,  we  believe  our  novel  IL-4R  antagonist  adjuvant  strategy  offers  great
promise  not  only  for HIV-1  vaccines,  but also  against  a range  of chronic  infections  where  sustained  high
quality  mucosal  and  systemic  T and  B  cell immunity  are  required  for protection.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Many licensed human vaccines are currently available for a wide
ange of bacterial and viral diseases; unfortunately it is evident that
onventional approaches to developing vaccines against chronic
nd challenging diseases such as HIV/AIDS, malaria or tuberculo-
is do not induce the correct “type” or level of immunity sufﬁcient
o prevent infection or control of the disease. This highlights the
mportance of developing innovative vaccine approaches that can
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induce sufﬁciently high level of protective immunity [1]. Surpris-
ingly, thirty years have passed since the discovery of HIV and the
exact correlates of the immune responses that potentially protect
against HIV infection or attenuate the development of AIDS are
still poorly understood. The development of an effective vaccine
against HIV/AIDS will require an in-depth understanding of the
antiviral immunity to HIV-1 and identifying and engineering the
desirable types of immunity required for protective efﬁcacy [2].
For example, understanding the mechanisms by which HIV evades
the immune system and tailoring the immunity to counteract such
immune escape may  be of importance. In addition, an in-depth
understanding of viral vaccine vectors utilised and how the vector’s
own intrinsic genetics and products inﬂuence the development
of the immune response needs to be understood to maximise
vaccine efﬁcacy. These features have been largely ignored in pre-
vious vaccine trials resulting in unexpected vaccine failures (e.g.
Adenovirus-based STEP trial).

































































[704 R.J. Jackson et al. / Vac
Multiple HIV-1 vaccines have been trialled over recent decades
hat although yielding good immune outcomes in animal mod-
ls have disappointingly failed to induce protective immunity in
uman clinical trials. Both the Adenovirus vectored HVTN505 and
he previous STEP vaccine trials were prematurely aborted due to
igniﬁcant numbers of vaccine subjects becoming infected with
IV [3]. The Thailand RV144 trial which used a canarypox virus
rime expressing HIV gag, pol and env (ALVAC) followed by a
rotein booster with recombinant envelope gp120 and adjuvant
AIDSVAC B/E) is the only vaccine to date to show any encourag-
ng results with a modest 31.2% protection [4]. Interestingly, these
wo vaccines when given individually failed to induce signiﬁcant
mmunity in humans [5,6]. Subsequent studies of the RV144 trial
ata indicated that antibody-dependent cell-mediated cytotoxic-
ty (ADCC) [7] and antibodies directed towards the V1/V2 region of
nv may  contributed to the protective immunity observed [8–10].
nterestingly, no neutralising antibodies or CD8 T cell mediated
mmunity were detected in this trial, which may  explain the par-
ial protection observed [4]. Since the RV144 trial, much of the
urrent HIV vaccine research efforts have been directed towards
nducing similar HIV-speciﬁc humoral immunity. Nonetheless,
ny successful future vaccine should also include the ability to
nduce high quality T cell mediated immunity for effective pro-
ective efﬁcacy. Notably, in HIV elite controllers the reduced viral
oads have been associated with cell-mediated immunity. Recent
tudies have shown that the HIV elite controllers have elevated
umbers of high avidity polyfunctional cytotoxic HIV Gag-speciﬁc
D8+ T-cells in the mucosae compare to the HIV progressors
11–13].
HIV transmits mostly via the genital tract or rectal mucosa and
he ﬁrst CD4 T cell depletion occurs in the gut mucosae [14]. It is
ow established that HIV is a disease of the mucosae, thus a mucosal
accine approach may  prove more useful in preventing and control-
ing HIV infection [15,16]. Unfortunately, due to the complexities
ssociated with delivery, safety and evaluation of vaccines efﬁcacy
n the mucosae, no mucosal HIV vaccine strategy has yet entered
linical development. Belyakov and co-workers have demonstrated
hat the intra-rectal immunisation induces local mucosal compart-
entalisation of CTL of high “functional avidity” and protection
f gastrointestinal CD4+ T cells from SHIV viral depletion in rhe-
us macaques compared to systemic delivery [17,18]. Consistent
o their ﬁnding we have also found that i.m. rDNA/i.n. rFPV can
nduce improved protection in macaques [19]. Since then in our
aboratory we have studied the immune outcomes induced follow-
ng mucosal and systemic heterologous prime-boost vaccination of
ntigenically distinct poxvirus vectors, Avipoxvirus fowlpox virus
FPV)-HIVgag/pol prime followed by an attenuated Orthopoxvirus
accinia virus (VV)-HIVgag/pol booster vaccination [20]. These
tudies have shown that according to the route of vaccine deliv-
ry the quality or avidity of HIV-speciﬁc CD8 T cells can be vastly
ifferent and speciﬁcally, IL-13 and IL-4 have an inhibitory inﬂu-
nce upon the development of high avidity CD8+ T cell responses.
ur data has demonstrated that (i) mucosal vaccination can induce
igh avidity HIV-speciﬁc CD8+ T cells with reduced IL-4/IL-13
ctivity and better protective efﬁcacy [21], (ii) IL-13 in the cell
ilieu has a direct negative impact upon CD8+ T cell avidity [22]
nd (iii) direct neutralisation of endogenous IL-13 activity using a
igh afﬁnity cytokine receptor, IL-13R2 adjuvanted HIV vaccines
elivered intranasal/intramuscular strategy can induce high avid-
ty systemic and mucosal HIV-gag speciﬁc CD8+ T cell responses,
ith enhanced cytokine/chemokine expression and greater protec-
ive efﬁcacy [23]. Surprisingly, transient inhibition of IL-13 activity
t the site of immunisation in wild-type mice generated similar
D8+ T cell responses in regards to avidity and anti-viral protection
s IL-13−/− gene knockout mice immunised with control vaccines
23].2 (2014) 5703–5714
Cytokines IL-4 and IL-13 share sequence similarity, cell sur-
face receptor subunits, intracellular signalling and relatively similar
functional effects on cells. The IL-4 receptor exists in two  forms,
the IL-4R chain which directly binds IL-4 is a common receptor
component for both the IL-4R type I (IL-4R/c) and type II (IL-
4R/IL-13R1), the latter complex also functions as the receptor
for IL-13 [24]. Cellular distribution of the receptors differs with
the type I receptor generally expressed by hematopoietic cells and
type II by non-hematopoietic cells due to differing expression of
the c and IL-13R1 subunits, while macrophages express both
type I and II receptors. Engagement of IL-4/IL-13 to the receptors
triggers cell signalling via JAK/STAT6 dependent mechanisms [25].
A second receptor, IL-13R2, binds IL-13 with high afﬁnity and is
thought to be a decoy receptor sequestering IL-13 [24], although
some studies suggest an uncharacterised signalling activity [26].
Previously, Ahlers et al. [27] demonstrated that soluble IL-13R2-
Fc decoy receptor together with GM-CSF and CD40L as molecular
adjuvants can enhance magnitude HIV Env-speciﬁc CD8+ CTL pep-
tide vaccine response. However, IL-13R2-Fc protein used alone
without other co-stimulators failed to enhance CTL magnitude or
activity. Consistent with this ﬁnding we have also found that, a
single administration of soluble IL-13R2-Fc protein together with
FPV-HIV made no difference in HIV-speciﬁc CD8+ T cell numbers
or T cell avidity [23]. In contrast, HIV vaccines co-expressing IL-
13R2 decoy receptor was able to sequester free IL-13 and greatly
enhance magnitude, functional avidity and poly-functionality of
the HIV Gag-speciﬁc CD8+ T cell response [23].
A number of IL-4 derivatives that either mutate or delete the
essential tyrosine residue found in the C-terminal region of both
human and mouse cytokines have been developed which bind to
cellular IL-4R with high afﬁnity without stimulating cell signalling
and block activation by both endogenous IL-4 and IL-13 [28–31].
To avoid introducing novel viral expressed “IL-4 antigens” due to
amino acid substitutions we  have constructed recombinant FPV
and VV co-expressing a soluble mouse IL-4 protein containing a
short C-terminal deletion encompassing the essential Y119, IL-
4C118, while retaining high afﬁnity binding to both IL-4R types
I and II and blocking IL-4/IL-13 cell signalling (see Suppl. Diagram
1).
In this study we  have evaluated the efﬁcacy of this novel IL-4R
antagonist HIV vaccine, speciﬁcally the ability to not only induce
high avidity CD8+ T cells but also B cell immunity. In this study
the HIV-speciﬁc T cell responses were evaluated against the BALB/c
Gag197–205 AMQMLKETI immune-dominant CD8 T cell epitope [32].
As we have previously shown that CD8+ T cells speciﬁc for the
immuno-dominant epitope represent approximately 80% of the
total Gag response in an FPV-HIV/VV-HIV immunisation setting
[33]. The B cell responses were measured against the total HIV P55
Gag protein.
2. Materials and methods
2.1. RT-PCR isolation of IL-4C118 cassette and DNA cloning
The mouse IL-4C118 cDNA was isolated using the reverse
transcriptase polymerase chain reaction (RT-PCR) method
and the Qiagen RT-PCR kit to amplify the cDNA from mouse
spleen total RNA. The following gene speciﬁc primers were
used to isolate the IL-4C118 cDNA; forward primer 5′-
GGATCCACCATGGGTCTCAACCCCCAGCTA, containing a terminal
BamHI restriction site and a consensus Kozak sequence overlap-
ping the IL-4 methionine codon (underlined) and reverse primer
5′-GAATTCTAATCCATTTGCATGATGCTC, containing a terminal
EcoRI site at the end and introduces a stop codon (underlined
complimentary sequence) to prematurely truncate the protein
R.J. Jackson et al. / Vaccine 3
Table  1
Prime boost vaccine strategies used in this study.
Prime Boost
1 i.n. FPV-HIV i.m. VV-HIV
2  i.n. FPV-HIV-IL-4C118 i.m. VV-HIV
3  i.n. FPV-HIV i.m. VV-HIV-IL-4C118
4  i.n. FPV-HIV-IL-4C118 i.m. VV-HIV-IL-4C118



















































oll rFPV and rVV constructs encode HIV-1 gag/pol antigens originating from (FPV086
nd VV336 respectively) [37]. i.n. intranasal, i.m. intramuscular.
a Note that for the IL-13R2 vaccine used here is the soluble form that was used
n  our previous study [23].
rior to tyrosine residue Y119. The resulting mutant protein
ontained a C-terminal aspartic acid at position 118 (IL-4C118) of
he mature protein following cleavage of the N-terminal signal
eptide. The 431 bp cDNA PCR fragment was ligated into pDrive
ector (Qiagen) and conﬁrmed by DNA sequencing. The IL-4C118
DNA was ligated between the BamHI and EcoRI sites of the VACV
ector pTK7.5A [34]. The pTK7.5A vector contains the herpes sim-
lex virus thymidine kinase (tk) gene as a selectable marker. The
L-4C118 cDNA was ligated into pBluscriptSK+ (Promega) and then
xcised as a BamHI–HindIII fragment and ligated into the multiple
loning site of the FPV vector pAF09 [35]. The IL-4 methionine
odon was positioned in-frame with the ATG of the poxvirus late
romoter contained in pAF09 to maximise translation. The pAF09
ector contains the Escherichia coli gpt gene to enable growth
election in the presence of mycophenolic acid and xanthine, and
he lacZ gene for colour selection of recombinant viral plaques.
.2. Isolation of recombinant viruses
Recombinant poxviruses were constructed essentially as
escribed [36] and brieﬂy described here. Recombinant VV336 con-
ains the insertion of the HIV gag/pol(mut) genes into VV tk gene
ausing the virus to have a TK-negative phenotype [37]. A recombi-
ant VV co-expressing HIV gag/pol and IL-4C118 was constructed
y transfection of VV336 infected HuTK-143B (ATCC CRL8303)
ells with pTK7.5A-IL-4C118 using Lipofectamine 2000 transfection
eagent (Invitrogen). Recombinant viruses expressing the herpes
implex virus TK were isolated using HuTK-143B cells and cul-
ure media containing HAT supplement (Sigma). Recombinant FPV
ere similarly constructed and isolated using parent virus FPV086,
hich expresses the HIV gag/pol protein [37], grown on primary
hicken embryo skin (CES) cells transfected with pAF09-IL4C118.
ecombinant FPV were selected and isolated in culture media con-
aining mycophenolic acid, xanthine and 1x HAT supplement to
elect for co-expression of the E. coli gpt gene. Recombinant viral
laques were identiﬁed for co-expression of the E. coli lacZ gene
sing an agarose overlay containing 200 g/ml X-gal [35,38]. Inser-
ion and expression of the mouse IL-4C118 gene was conﬁrmed
y PCR for the inserted DNA sequence and immuno-blotting for
ecreted IL-4 protein (see Suppl. Fig. 1).
.3. Immunisation of mice and protection against surrogate
ecombinant inﬂuenza-HIV challenge
Pathogen free 6–7 week old female BALB/c (H-2d) mice were
btained from the Animal Breeding Establishment, John Curtin
chool of Medical Research (JCSMR). All animals were maintained
nd used in accordance with the Australian National Univer-
ity (ANU) animal experimentation ethics committee approved
uidelines. Mice (n = 4–8 per group) were prime-boost immunised
.n./i.m. with 1 × 107 plaque forming units (PFU) rFPV followed
y 1 × 107 PFU rVV expressing HIV-1 antigens and IL-13R2 or
L-4C118 antagonist as described in Table 1 under mild methoxyﬂu-
rane anaesthesia two weeks apart. Similarly groups of mice2 (2014) 5703–5714 5705
were used as unimmunised controls. Immediately prior to deliv-
ery the viruses were diluted in phosphate buffered saline (PBS)
and sonicated 20–30 s to obtain an homogeneous viral suspension,
intranasal rFPV was given in a ﬁnal volume of 20–25 l and i.m. rVV
were delivered, 50 l per quadriceps.
To evaluate CD8 T cell mediated protective immunity, 6 weeks
post booster vaccination, immunised and unimmunised mice were
challenged intranasally with 75–100 PFU of inﬂuenza virus PR8
expressing the KdGag197–205 epitope of HIV as described previously
[23]. Body weight was monitored for 9–10 days after challenge. The
attenuated recombinant inﬂuenza virus PR8-KdGag197–205 incorpo-
rates the H2-Kd restricted immuno-dominant epitope AMQMLKETI
[32] into the inﬂuenza virus neuraminidase stalk, constructed as
described by Cukalac et al. [39]. Intra-nasal challenge of naïve
BALB/c (H2-Kd) mice with PR8-KdGag197–205 induces signiﬁcant
weight loss, followed by weight gain as the mice recover from a mild
ﬂu, over a 10 day period. The cells infected with PR8-KdGag197–205
present the MHC-I restricted HIV-Gag epitope, and in HIV Gag
immunised mice CD8+ CTL speciﬁc for HIVGag197–205 will kill the
infected cells limiting replication and dissemination of the recom-
binant inﬂuenza virus signiﬁcantly reducing weight loss. The ability
to maintain body weight speciﬁcally at peak infection (4–7 days) is
considered a measure of CD8+ T cell mediated protective immunity
not antibody immunity.
2.4. Preparation of mucosal and systemic lymphocytes
To measure systemic and mucosal T cell responses mice were
euthanized at different time intervals (2 and 8 weeks) post-boost
immunisation, and 10 days post inﬂuenza-KdGag197–205 challenge;
spleen, genito-rectal nodes (GN) or iliac lymph nodes and Peyer’s
patch (PP) were removed and cell suspensions prepared in com-
plete (5% FBS) RPMI as described previously [20,40,41].
2.5. Tetramer staining and dissociation assays
Allophycocyanin-conjugated KdGag197–205 tetramers were syn-
thesised at the Bio-Molecular Resource Facility at The John
Curtin School of Medical Research (BRF/JCSMR), ANU. 2–5 × 106
splenocytes or mucosal lymphocytes were stained with anti-CD8-
FITC antibody (Biolegend, USA) and Allophycocyanin-conjugated
KdGag197–205 tetramer at room temperature and analysed as
described previously [20,40,42]. All the appropriate controls were
performed and the background tetramer counts in naïve mice were
found to be between 0.05 and 0.5% in spleen, 0.02–0.05% in mucosal
tissue and GN. Also following KdGag197–205 tetramer staining the
dissociation assays were performed as described before [21,43]. In
these assays, plates were conﬁgured to include ﬁve time points per
sample (0–60 min). 50 g/ml of anti-H-2Kd competitive binding
antibody (BD PharMigen, San Diego, USA) was added to each well to
prevent dissociated tetramer from re-binding and plates were incu-
bated at 37 ◦C, 5% CO2. At each time point, cells were transferred
into ice-cold FACS buffer to stop the reaction, washed and resus-
pended in 100 l of FACS buffer containing 0.5% paraformaldehyde.
100,000 events were acquired on a FACs Calibur ﬂow cytometer
(Becton-Dickinson, San Diego, USA) and analysed using Cell Quest
Pro software. In tetramer dissociation assays, lower dissociation
rates or stronger MHC-I/peptide complex binding to the TCR com-
plex of CD8 T cell, is associated with higher avidity [43].
2.6. IFN- and IL-2 ELISpot assaysIFN- or IL-2 capture ELISpot assays was used to assess IFN-
 or IL-2 HIV-speciﬁc T cell responses [40]. Brieﬂy, 2 × 105 spleen
or GN cells were added to 96-well Millipore PVDF plates (Milli-
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apture antibodies (BD PharMigen, San Diego, CA), and stimulated
or 12 h or 22 h respectively for IL-2 or IFN- ELISpot, in the pres-
nce of H-2Kd immuno-dominant CD8+ T cell epitope, Gag197–205
MQMLKETI (synthesised at the Bio-Molecular Resource Facility
t JCSMR). ConA-stimulated cells (Sigma, USA) were used as posi-
ive controls and unstimulated cells as negative controls. For both
LISpot assays, all steps were carried out exactly as described previ-
usly [20,40]. The graphed data are expressed as SFU (spot-forming
nits) per 106 T cells and represent mean values ± SD. Unstimu-
ated cell counts were subtracted from each stimulated value before
lotting the data. In all assays the background SFU counts were
etween 4–10 SFU for IFN- and 5–18 SFU for IL-2 ELISpot. Also
he unimmunised animals did not show any responses following
ag197–205-AMQMLKETI stimulation.
.7. Intracellular cytokine staining (ICS)
IFN- and TNF- producing HIV-speciﬁc CD8 T cells, were ana-
ysed as described in Ranasinghe et al. [20,40]. Brieﬂy, 2 × 106
ymphocytes were stimulated with AMQMLKETI peptide at 37 ◦C
or 16 h, and further incubated with Brefeldin A (eBioscience, CA,
SA) for 4 h. Cells were surface-stained with CD8-Allophycocyanin
Biolegend, USA) then ﬁxed and permeabilized prior to intracellu-
ar staining with IFN--FITC and TNF--PE (Biolegend, USA). Total
00,000 gated events per sample were collected using FACS Cal-
bur ﬂow cytometer (Becton Dickinson, San Diego, CA), and results
ere analysed using Cell Quest Pro software. Prior to plotting the
raphs the unstimulated background values were subtracted from
he data, The IFN-+ cell counts were less than 0.05–0.1% in unim-
unised or unstimulated samples similar to our previous studies
23].
.8. HIV-1 P55 Gag-speciﬁc serum enzyme-linked
mmunosorbent assay (ELISA)
Female BALB/c mice n = 8 were i.n./i.m. prime-boost immunised
sing the strategies 1, 4 and 5 indicated in Table 1. ELISA was
sed to determine HIV-1 p55 gag-speciﬁc IgG1 and IgG2a serum
ntibody titres similar to as described in Ranasinghe et al. [40].
alcon microtest III plates were coated with HIV-1 p55-gag (sup-
lied by the NIH AIDS research and reference reagent programme)
t 1 g/ml (50 l/well) in borate buffer (Pierce) overnight at 4 ◦C.
he plates were washed 5 times with 0.05% Tween20 in PBS (PBST)
nd nonspeciﬁc binding sites were blocked by adding 200 l of 5%
kim milk in PBST incubated at 37 ◦C for 2 h. The plates were then
ashed as before, the serum samples were then diluted 2 fold (IgG1
:800–1:25600, IgG2a 1:200–1:6400) in 5% skim milk/PBST and
0 l added to each well. The plates were incubated at 37 ◦C for
 h washed as before, secondary antibody, biotin-conjugated goat
nti-mouse IgG1 or goat anti-mouse IgG2a (Southern Biotechnol-
gy Associates, Birmingham, AL) was diluted to 1:500 in 1% bovine
erum albumin/PBST (Sigma) (BSA/PBST) was added to respec-
ive wells in a 50 l volume, and incubated overnight at 4 ◦C. The
lates were washed in PBST and 50 l of streptavidin horseradish
eroxidise (Amersham Biosciences) diluted 1:500 in 1% BSA/PBST
as added and incubated at 37 ◦C for 2 h. Next the antibodies
ere detected using 0.01 mg/ml  tetramethyl-benzidine (Sigma)
ubstrate dissolved in dimethyl sulfoxide (Sigma) diluted in cit-
ate/phosphate substrate buffer (Sigma) and incubated for 30 min
t room temperature. The optical densities (OD) were measured at
05 nm using a Tecan Inﬁnite m200 Pro Spectrometer..9. Statistics
For T cell-based assays SD or SEM were calculated and p-
alues determined using a two-tailed, two sample equal variance2 (2014) 5703–5714
or unequal variance Student’s t-test or one-way ANOVA to com-
pare the groups, followed by post hoc analysis with Sidak multiple
comparison test using IBM, SPSS (formerly known as Statistical
Package for the Social Sciences) statistical software version 21.
Except where stated, experiments were repeated at least three
times. To determine endpoint titres, serum from unimmunised
mice was  titrated across an ELISA plate beginning at the same dilu-
tion as the samples. The samples were considered as positive when
the OD was  at least 3 times the unimmunised mouse serum. Sam-
ple that were found not be positive were assigned the titre of half
the ﬁrst dilution. The serum antibody responses were compared
using the Mann–Whitney U test was  performed using Prism soft-
ware version 6.02 (Graphpad Inc.) and these antibody experiments
were repeated two  times.
3. Results
3.1. HIV-1 vaccines that co-express IL-4R antagonist induces high
avidity CD8+ T cell immunity
When BALB/c mice were i.n./i.m. prime-boost immunised using
the IL-4R antagonist vaccine as described in Table 1 (strategies
2–4), and the CD8+ T cell avidity was evaluated using tetramer
dissociation assays, which is a direct measurement of the bind-
ing strength of the tetramer MHC-I/peptide to the TCR/complex
of the HIV-speciﬁc CD8 T cell. This measurement is independent
of the numbers of tetramer positive cells in the sample or the
ability of a CD8 T cell to express IFN- upon peptide stimulation.
(Note: high avidity CD8 T cells the dissociation rate is slower com-
pared to low avidity CD8 T cells which shows a higher dissociation
rate [21,43]), The data indicated that FPV-HIV-IL-4C118/VV-HIV-IL-
4C118 immunisation induced KdGag197–205-speciﬁc CTL of higher
avidity compared to control vaccination (p = 0.01) (Fig. 1). More-
over, the data again demonstrate that inclusion of the antagonist
in the prime, and not the booster, was  essential for the generation
of high avidity T cells (FPV-HIV/VV-HIV vs. FPV-HIV-IL-4C118/VV-
HIV) (p = 0.025), as inclusion of the IL-4R antagonist in the booster
induced KdGag197–205-speciﬁc CTL that were of similar avidity to
control vaccination (Fig. 1). These results are similar to that of IL-
13R2 adjuvanted vaccine data observed previously [23].
3.2. IL-4R antagonist adjuvanted vaccines induce enhanced
HIV-speciﬁc systemic and mucosal effector and memory CD8+ T
cell responses
Next we  evaluated the number of KdGag197–205 tetramer reac-
tive cells induced by the IL-4C118 antagonist vaccination. Data
indicated that i.n. FPV-HIV-IL-4C118/i.m. VV-HIV-IL-4C118 prime-
boost immunisation induced signiﬁcantly greater numbers of
KdGag197–205 tetramer reactive systemic CD8+ T cells (∼average
20%) (Fig. 2), compared to the control FPV-HIV/VV-HIV prime-boost
immunisation (∼average 7%) (p = 0.0001). Interestingly, when the
adjuvant was delivered only in the prime (Table 1 strategy 2)
the magnitude of systemic KdGag197–205-speciﬁc tetramer reac-
tive cells were very similar to the control vaccination (Fig. 2).
However, when the IL-4C118 adjuvant was  only delivered in the
booster vaccination (Table 1 strategy 3) even though signiﬁcantly
elevated numbers of KdGag197–205 tetramer-speciﬁc T cells were
detected compared to the control or the prime only groups (Fig. 2)
(p = 0.0001, and p = 0.018, respectively), the KdGag197–205-speciﬁc
T cell avidity of i.n. FPV-HIV/i.m. VV-HIV-IL-4C118 prime-boost
immunised group was  comparable to that of the control vaccine
strategy (Fig. 1). These results were similar to what was observed
with IL-13R2 adjuvanted vaccine strategy [23].
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Fig. 1. Avidity of HIV-speciﬁc CD8+ T cells following IL-4R antagonist vaccine compared to the control. BALB/c mice (n = 4–5 per group) were i.n./i.m. prime-boost immunised
with  FPV-HIV/VV-HIV and the recombinant pox virus vaccines co-expressing IL-4R antagonist as indicated in Table 1. 14 days post booster immunisation, percentage of
KdGag197–205 positive CD8+ splenocyte loss (dissociation) was  measured as described in material and methods. Graph (A) indicates the IL-4R antagonist used in prime and




















Iblack  dotted line). Data represent mean ± SD and the p values were calculated using
C118/i.m. VV-HIV-IL-4C118 (p = 0.010) and FPV-HIV/VV-HIV vs. FPV-HIV-IL-4C118
s.  FPV-HIV/i.m. VV-HIV-IL-4C118 group.
Furthermore, the ability of HIV-speciﬁc CD8+ T cells to produce
FN- following KdGag197–205 stimulation were evaluated both in
ystemic (splenic) and mucosal compartments (iliac or genito-
ectal nodes) (Fig. 3A and B). Data indicated that i.n. FPV-HIV-IL-
C118/i.m. VV-HIV-IL-4C118 prime-boost immunisation strategy
lso induced elevated numbers of splenic effector CD8+IFN-+  T
ells (∼18%) compared to the control vaccine strategy (∼6%) (Fig. 3A
nd C) measured by ICS. The splenic IFN- ICS response pattern was
ighly consistent with the tetramer data observed in Fig. 2. Our data
learly indicated that our novel IL-4R antagonist vaccine strategy
an also induce elevated mucosal HIV-speciﬁc CD8+IFN-+  T-cell
























ig. 2. HIV-speciﬁc tetramer reactive CD8+ T cell responses post IL-4C118 adjuvanted vac
IV/VV-HIV and/or rFPV or rVV vaccines co-expressing IL-4R antagonist (as indicated in T
ells  was  evaluated in spleen. The data represent mean +SD. All the p values were calculat
as  performed with Sidak multiple comparison test using IBM, SPSS (formerly known 
IV/VV-HIV vs. FPV-HIV/VV-HIV IL-4C118 (p = 0.0001); FPV-HIV/VV-HIV vs. FPV-HIV IL-4C
L-4C118 (p = 0.018) and FPV-HIV IL-4C118/VV-HIV vs. FPV-HIV IL-4C118/VV-HIV IL-4C11tailed, two sample equal variance Student’s t-test. FPV-HIV/VV-HIV vs. FPV-HIV-IL-
V-HIV (p = 0.025). No signiﬁcant differences were found between FPV-HIV/VV-HIV
CD8+ T cells are known to correlate with protective immunity,
therefore we  next assessed the ability of CD8+ T cells to express
IFN-, TNF- and IL-2. Interestingly, the data indicated that number
of polyfunctional HIV-speciﬁc T cells; IFN- and TNF- (p = 0.021)
(Fig. 3D) and IFN-, TNF- and IL-2 (p = 0.005) (Fig. 3E) were also
signiﬁcantly elevated in the IL-4C118 adjuvanted vaccine group
compared to the mice that received the control vaccine. Further-
more, the above strategy was  also able to induce elevated numbers
+ +of CD8 IFN- (consistent to our ICS data) and IL-2 effector HIV-
speciﬁc CD8+ T cells in iliac nodes compared the control vaccine
(Fig. 4) as measured by ELISPOT. The evaluation of polyfunc-
tional HIV-speciﬁc CD8+ T cells (speciﬁcally IL-2) in mucosal sites
FPV HIV/VV HIV  
FPV HIV IL-4C118/VV HIV  
FPV HIV/VV HIV IL-4C118 
FPV HIV IL-4C118/VV HIV IL-4C 118  
cination. BALB/c (n = 5 per group) were i.n./i.m. prime-boost immunised with FPV-
able 1). 14 days post booster immunisation, percentage of KdGag197–205 positive T
ed ﬁrstly, using one-way ANOVA to compare the groups and next post hoc analysis
as Statistical Package for the Social Sciences) statistical software version 21. FPV-
118/VV-HIV IL-4C118 (p = 0.0001); FPV-HIV-IL-4C118/VV-HIV vs. FPV-HIV/VV-HIV
8 (p = 0.016). These experiments were repeated over three times.
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VV-HIV IL-4C 118  
* 
* p = 0.021 ** p = 0.005  
** 
Fig. 3. Cytokine expression by systemic HIV-speciﬁc effector CD8+ T cells. Mice (n = 5) were immunised i.n./i.m. as in Table 1 (strategies 1, 2, 3 and 4) and at 14 days prime-
boost  immunisation, IFN-, TNF- and IL-2 protein expression in spleen (A) and genito-rectal nodes or iliac nodes (B) were evaluated by ICS following AMQMLKETI gag












phe  p values were calculated using two-tailed, two  sample equal variance Student’s
iliac nodes) by ICS is a challenging task due to small sample size.
owever, we have found that when mucosal HIV-speciﬁc CD8+
 cell immunity is evaluated speciﬁcally at the gut mucosae at a
ingle cell level using Fluidigm Biomark analysis, the IL-4R antag-
nist vaccination can induce enhanced expression of many other
mmunomodulatory cytokines/chemokines, granzymes and per-
orins compared to the control vaccination [80]. Interestingly, these
levated systemic/mucosal CD8+IFN-+ T cells responses were also
ound to be long lived as elevated responses were detected at 8
eeks post booster vaccination. Spleen control vaccine vs. IL-4C118
 = 0.012 (Fig. 5A and B).. These experiments were repeated three times.
3.3. IL-4R antagonist adjuvanted vaccines induce both excellent
serum IgG1 and IgG2 antibody responses
As it is thought that inhibition of Th2 cytokine activity could
potentially dampen antibody responses, we also evaluated whether
the IL-4C118 antagonist and IL-13R2  adjuvanted vaccines can also
induce B cell mediated immunity towards HIV Gag. Female BALB/c
mice n = 8 were immunised i.n./i.m. with the vaccines indicated in
Table 1 (strategies 1, 4 and 5), HIV p55 gag speciﬁc serum IgG1
and IgG2a antibody responses were evaluated at 3-week inter-
vals for 12 weeks following the booster vaccination (Fig. 6A–C).
R.J. Jackson et al. / Vaccine 3
Fig. 4. IFN- and IL-2 expression by mucosal HIV-speciﬁc CD8+ T cells were eval-
uated in genito-rectal nodes 14 days post prime-boost immunisation by ELISpot
following AMQMLKETI gag peptide stimulation. CD8+IFN-+ and CD8+IL-2+ were
evaluated and data were plotted after subtracting the background cell counts (which
were less than 4–18 SFU). The error bars represent mean ± SD. These experiments


















response can be generated in the absence of IL-13, with enhanced
protective efﬁcacy following a surrogate inﬂuenza-HIV challenge





rhe absorbance data indicates that the p55-speciﬁc IgG1 antibody
esponses trend generated by all three vaccines were similar across
he 12-week period (Fig. 6A). The endpoint titres at 12 weeks
ere approaching signiﬁcance (p = 0.0587) between the IL-4C118
ntagonist and IL-13R2 immunised groups (Fig. 6B). Interestingly,
he p55-speciﬁc IgG2a antibody responses consistently increased
ollowing IL-4C118 antagonist vaccine compared to IL-13R2 vac-
ines across the 12-weeks (Fig. 6A and C). The endpoint titres clearly
ndicated that the IL-4C118 antagonist vaccine could induce sig-
iﬁcantly higher p55-speciﬁc IgG2a antibody titres at 6, 9 and
2 weeks (Fig. 6C). At 6 weeks the control vaccine was also sig-
iﬁcantly (p = 0.0256) higher than the IL-13R2 vaccine (Fig. 6C).
rom the both the absorbance trends and the endpoint titre data it
as evident that the IL-13R2  vaccine regime has suppressed the
nduction of p55 IgG2a antibodies while having no signiﬁcant effect
pon IgG1 response, the IL-4C118 antagonist elicited comparable



























ig. 5. HIV-speciﬁc memory T cell responses post IL-4C118 adjuvanted vaccination BALB
PV-HIV/VV-HIV (black) and FPV-HIV-IL-4C118/VV-HIV-IL-4C118 (grey) as indicated in Ta
nd  2x105 lymphocytes were cultured in the presence of AMQMLKETI gag peptide in an 
esponses in spleen (A) and genito-rectal nodes (B). The background cell counts (which
epresent mean ± SD and the p values were calculated using two-tailed, two  sample equa2 (2014) 5703–5714 5709
3.4. IL-4C118 antagonist induces excellent protective immunity
Finally we assessed the protective efﬁcacy of the novel IL-4C118
vaccine compared to our previously tested IL-13R2 adjuvanted
and the control vaccines [23], using a surrogate attenuated recom-
binant inﬂuenza virus PR8-KdGag197–205 challenge to evaluate
CD8+ T cell mediated immunity. In this study, eight weeks fol-
lowing booster immunisation, mice were challenged intranasally
with 75–100 PFU of inﬂuenza virus expressing the KdGag197–205
immunodominant epitope and body weights were monitored daily
for 9–10 days. Mice that received the i.n. FPV-HIV-IL-4C118/i.m.
VV-HIV-IL-4C118 vaccination showed better protective efﬁcacy
compared the previously tested IL-13R2 adjuvanted vaccines [23]
(Fig. 7A and B). The IL-4C118 and adjuvanted group showed sig-
niﬁcantly higher (p < 0.05) recovery rates compared to the wild
type BALB/c mice that received the control vaccination, speciﬁ-
cally at peak inﬂuenza infection (Fig. 7A). The above protective data
were also consistent with the slower dissociation rates (Fig. 1) the
enhanced KdGag197–205 tetramer CD8+ T cell staining (Fig. 2) and
the polyfunctional IFN-/IL-2 CD8 T cell responses observed in the
systemic and mucosal compartments (Fig. 4), following immun-
isation with the IL-4C118 antagonist vaccine. As shown in Fig. 6,
both IgG1 and IgG2a anti-Gag p55 responses were similar between
mice immunised with either the control or the IL-4C118 adjuvanted
vaccines. Suggesting that antibody had little inﬂuence upon the
outcome of the PR8-KdGag197–205 challenge and the difference in
immune protection observed was determined predominantly by
the HIV-Gag speciﬁc CD8+ T cell response.
4. Discussion
We have previously demonstrated that the i.m./i.m. poxvirus
vectored heterologous prime-boost vaccine strategy induces ele-
vated numbers of HIV-speciﬁc CD8+ T cells of lower avidity
expressing IL-4 and IL-13 compared to a purely mucosal vaccina-
tion [20,21]. These studies also demonstrated that the magnitude
of HIV-speciﬁc CTLs did not correlate with the avidity measured by
MHC-1/CD8 T cell interaction. Using gene knockout mice it was













/c (n = 5 per group) were i.n./i.m. prime-boost immunised with control vaccination
ble 1. Eight weeks post booster immunisation, single cell suspensions were prepared
ELISpots were performed as described in Methods. The graphs represent the IFN-
 4–10 SFU for IFN- ELISpot) were subtracted before plotting the data. Error bars
l variance Student’s t-test. These experiments were repeated three times.
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Fig. 6. The p55-gag speciﬁc IgG1 and IgG2a antibody trends and endpoint titres following prime-boost immunisation. Female BALB/c mice (n = 8 per vaccine group) were
immunised with control vaccine FPV-HIV/VV-HIV, FPV-HIV-IL-13R2/VV-HIV-IL-13R2 or FPV-HIV IL-4C118/VV-HIV IL-4C118 vaccines (regimes 1, 4 and 5, Table 1) and the
serum  was collected at 3-week intervals following the booster vaccination and analysed for p55-gag speciﬁc IgG1 and IgG2a antibodies. (A) Graphs represent the trends of the
serum  dilutions 1:3200 for IgG1 (left) and 1:400 for IgG2a (right) 3, 6, 9 and 12 weeks post booster vaccination. The y-axis indicates the absorbance (wavelength of 405 nm)
and  the x-axis indicates the time intervals post boost immunisation. (B and C) Graphs represent the end point titres. To calculate the p55-gag speciﬁc IgG1 (B) and IgG2a (C)
endpoint titres, serial serum dilutions were performed and the endpoints were calculated as described in methods statistical analysis section. The errors bars represent the
±SEM  and the p values were calculated using the Mann–Whitney U test. These experiments were repeated two times.
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Fig. 7. Protective immunity following PR8-KdGag197–205 challenge. BALB/c mice (n = 5–8 per group) were i.n./i.m. prime-boost immunised FPV-HIV/VV-HIV and/or rFPV or








































4ith  75–100 units inﬂuenza virus PR8 expressing KdGag197–205 epitope. Body weigh
nd  *p values at peak of infection calculated using two-tailed, two  sample unequal 
opulation following vaccination. The current studies demon-
trated that the IL-4C118 adjuvant, an antagonist for both type I/II
L-4R receptors which blocks both IL-4 and IL-13 cell signalling (see
uppl. Diagram 1), included in both the prime and booster HIV vac-
ine strategy (i) signiﬁcantly enhanced HIV speciﬁc KdGag197–205
ositive CD8+ T cell response (average 20% of total CD8+ T cells),
ompared to the non-adjuvant vaccine eliciting average 7% of CD8+
 cells, (ii) induced enhanced numbers of effector and memory
ucosal and systemic HIV speciﬁc CD8+ T cells that expressed IFN-
, TNF- and IL-2 which associated with high avidity T cells of better
rotective efﬁcacy following a surrogate inﬂuenza-KdGag197–205
hallenge, compared to the control vaccination. Induction of multi-
unctional T cells expressing IFN-, IL-2 and TNF- is considered a
allmark of high avidity T cells with protective efﬁcacy towards HIV
45–47]. These features are also characteristic of elite controllers
f HIV whose HIV speciﬁc CD8+ T cells are of high avidity, with
levated multifunctional capacity and viral control [48,49].
Our previous ﬁndings indicate that the avidity of the resul-
ant HIV speciﬁc CD8+ T cell repertoire was determined during
he priming immunisation [23], this is highly consistent with our
urrent ﬁndings where delivering the IL-4C118 adjuvant in the
oost only, resulted in a major increase in magnitude of the HIV
peciﬁc T cell response, without signiﬁcant avidity enhancement.
he results presented here and our recent ﬁndings indicate that
L-4/IL-13 not only have signiﬁcant effects during the induction
f the immune response but also affect the functions of acti-
ated CD8+ T cells which regulated responsiveness to IL-4/IL-13
y reducing cell surface expression of IL-4R [50] and also reg-
lating CD8 co-receptor expression with direct effects on the
vidity of CD8+ T cells [51]. The inhibition of IL-13 activity by
L-13R2 adjuvanted vaccine [23] was shown to signiﬁcantly
p-regulate CD8 co-receptor expression on KdGag197–205-speciﬁc
D8+ T cells and this correlated with enhanced TCR avidity and
oly-functionality [51]. Interestingly, we have also demonstrated
hat mucosal vaccination induces high avidity HIV-speciﬁc T cells
ith lower IL-4/IL-13 expression and higher CD8-coreceptor den-
ities were detected on KdGag197–205-speciﬁc T cells compared to
.m./i.m. delivery [51] On the contrary, co-expression of active IL-
 by a recombinant VV resulted in enhanced IL-4R expression,re monitored for 10 days as described in Section 2. The data represent mean ± SEM
ce Student’s t-test. These experiments have been repeated two times.
reduced CD8 levels on CD8 T cells, reduced avidity and signiﬁcantly
reduced IFN- and TNF- expression [50,51]. Indeed earlier studies
using pathogenic Orthopoxviruses expressing IL-4 were shown to
severely curtail the development of effective cytotoxic cell medi-
ated immunity with the mice unable to control infection [52,53].
As the avidity of a CD8+ T cell can change during the course of
an infection [54] and similarly the avidities of different CD8 epi-
topes are know to be vastly different [43], the true efﬁcacy of the
these novel vaccine expressing respective receptors should next be
evaluated in a non-human primate model following an SIV chal-
lenge.
The heterologous FPV-HIV/VV-HIV vaccine strategy was origi-
nally designed to elicit a CD8+ T cell mediated immunity towards
HIV gag/pol antigen via intracellular processing and MHC-I presen-
tation, however poxviruses can also be good inducers of sustained
antibody responses towards viral antigens, one of the features
attributed to the long lasting effects of the smallpox vaccine [55].
Previous studies involving co-expression of type-1 cytokines, e.g.
IL-2, IL-12, IFN-, by viral vaccines to enhance cell-mediated immu-
nity has been associated with reduced serum antibody levels
[52,56,57]. Co-expression of type-1 cytokines can also result in vari-
able outcomes, and as shown in several studies can be deleterious to
the resultant cell mediated response [20,52,57]. Speciﬁcally, inap-
propriately timed type-1 cytokine expression and polarisation of
Th1 immunity in some circumstances can be counterproductive
to both cell mediated and humoral responses. Examination of the
anti-HIV p55-gag response following control i.n. FPV-HIV/i.m. VV-
HIV prime-boost immunisation demonstrated signiﬁcant levels of
both IgG1 and IgG2a in the sera of mice. More surprisingly, follow-
ing immunisation of mice with the IL-4C118 adjuvant HIV vaccine,
which induced enhanced high avidity HIV speciﬁc CD8+ T cells with
IL-2 and IFN- expression also induced elevated HIV p55-gag IgG2a
antibody responses six weeks post booster vaccination and was
sustained over time.
The recent RV144 trial included both a canarypox virus (very
similar to rFPV) expressing gag/pol/env antigens followed by a
protein booster to enhance the anti-env humoral response. In
that study the 31% protective efﬁcacy observed was linked to
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ere observed, which may  explain the partial protective efﬁcacy.
nterestingly, isotype switching and high levels of IgG2 antibodies
irected towards the gag protein have been linked to protection,
peciﬁcally in HIV controllers not carrying the ‘protective’ human
eucocyte antigen HLA B alleles [58]. Although, the mechanism
y which gag-speciﬁc antibodies provided delayed progressions
emains unknown, in some HIV controllers, antibodies have shown
o play a role in ADCC [59,60]. It has been thought that production
f IFN- and gag-speciﬁc antibodies particularly IgG2 may  provide
timulation of plasmacytoide DC’s, which are typically reduced in
IV infected patients but not in controllers [61,62]. These observa-
ions suggest that induction of gag-speciﬁc antibodies could play a
ivotal role in providing the best protection possible against HIV-
. Our IL-4R antagonist vaccine has shown to induce excellent long
asting IgG2a antibody immunity. The induction of both high qual-
ty T and robust B cell immunity make our IL-4R antagonist HIV
accine a good candidate for the future.
Considering the similarity of the T cell responses between the
L-4C118 adjuvant HIV vaccine and our previous IL-13R2 adju-
anted vaccine study [23] the majority of the observed effects on
he induced quality of HIV speciﬁc CD8+ T cell responses are likely
ue to the inhibition of IL-13 cell-signalling via the type-II IL-4R
IL-4R/IL-13R1). Sequestration of IL-13 using a decoy IL-13R will
educe IL-13 binding to both type II IL-4R and plasma membrane
L-13R2, however IL-4 will still available to engage with type-
/II IL-4R for signalling. In contrast, expression of the IL-4C118
ntagonist will block both type-I/II IL-4R to IL-4 and IL-13 medi-
ted signalling, however plasma membrane IL-13R2 could still
ind free IL-13 (see Suppl. Diagram 1). Although the two different
djuvanted vaccines induced very similar high quality CD8+ T cell
esponses, the differential cytokine-receptor interactions between
he vaccines resulted in signiﬁcantly different HIV p55-gag IgG2a
ntibody proﬁle, IL-4C118 antagonist showing elevated responses
ompared to IL-13R2  adjuvanted vaccine. This is suggestive of two
ossible mechanisms of signalling (i) IL-4 signalling via IL-4R is
ntagonistic to IFN- dependent [63] or independent [64] B cell
gG2a isotype class switching retarding both control vaccine and IL-
3R adjuvant vaccine IgG2a responses. Whereas, with the IL-4C118
djuvant vaccine IL-4 is unable to stimulate cell signalling resulting
n enhanced and early HIV gag/pol speciﬁc IgG2a isotype switch-
ng following prime-boost vaccination. (ii) Alternatively, signalling
ia the IL-13R2 receptor in the absence of IL-4R signalling can
nﬂuence B cell maturation and IgG2a class switching during the
h1 inﬂuenced humoral response. Collectively, the data indicate
hat these IL-4/IL-13 receptors are important players in modulating
rotective immunity.
Our previous studies have shown that rFPV is an excellent
ucosal delivery vector compared to rVV [19,20,40] and the
riming immunisation determines the avidity of the CD8+ T
ell repertoire induced [23]. We  have recently completed an
nalysis of lung-derived DC (LDC) subsets induced 24 h follow-
ng intranasal immunisation of mice [80]. Interestingly, unlike
ther pox viral vectors tested rFPV priming was shown to
nduce a unique CD11b+ CD103− LDC population and adoptive
ransfer studies demonstrated that the unlike CD103+ LDC the
D103− LDC population favoured the induction of high avid-
ty CD8 T cells following immunisation. Interestingly, both the
L-13R2 and IL-4C118 adjuvant vaccines induced higher num-
ers of the CD11b+ CD103− LDC population relative to the
ontrol which correlated with proliferation of high magnitude,
trong avidity HIV speciﬁc CD8+ T cell responses and protec-
ive immunity. Differences in CD11b− B200+ and CD11b− CD8+DC subsets were also detected between the IL-13R2 and IL-
C118 adjuvant vaccines. These changes in the LDC populations
re indicative of the effects of endogenous IL-4/IL-13 are inﬂu-
ncing the innate immune response, imprinting the quality of the2 (2014) 5703–5714
downstream adaptive cell mediated and humoral immune out-
comes [80].
These observations and the current results raise the question;
what is the source of IL-13 during the innate response? While IL-
13 and IL-4 are traditionally thought to be expressed by Th2 CD4+
cells, recent studies have identiﬁed an additional important cellular
source of IL-13 early in the immune response. Innate lymphoid cells
(ILC) are emerging as central effectors of innate and adaptive immu-
nity and tissue remodelling [65,66]. Activated type 2 ILC (ILC2) cells
are critically required for orchestrating Th2 immune responses,
expulsion of extracellular parasites, maintaining tissue homeosta-
sis and are the main mediators of allergy and asthma [67–69].
Following injury/infection, epithelial cells release cytokines IL-25
and IL-33 which activate ILC2 cells to express IL-5, IL-9, IL-13, and
potentially small amounts of IL-4 [69]. Following intranasal infec-
tion of mice with a recombinant inﬂuenza A virus, activated ILC2
accumulate in the lung and express not only IL-5, IL-9, IL-13 but also
amphiregulin (Areg), the ligand for EGFR which drives epithelial
cell proliferation and tissue repair [70]. In the context of an attenu-
ated vaccine similar ILC2 activation and IL-13 expression will have
a negative impact upon the resulting quality and magnitude of the
Th1 anti-viral response. Potential additional sources of IL-4 dur-
ing innate responses may  include stimulation of basophils [71] and
activated iNKT2 cells [72].
Poxviruses devote a large proportion of the genomic informa-
tion to express factors that modulate and evade the host’s antiviral
innate and adaptive immune responses [73]. Of particular rele-
vance to this study are factors secreted from pox virus infected cells
which modulate the balance of Th1 and Th2 immunity. VV is known
to express soluble type-I and type-II IFN binding proteins which
sequester IFN- and IFN-, respectively [74,75] VV also expresses
soluble high afﬁnity decoy receptors for TNF-, and IL-18 which
bind and prevent these cytokines from interacting with the nat-
ural receptors [76,77]. Poxviruses apply signiﬁcant resources into
reducing the activity of these antiviral cytokines which are required
for activation of type-1 ILC i.e. type-I IFNs and IL-18, or neutralise
the major secreted antiviral products, i.e. IFN-, TNF-. IL-18 is
critical for strong antiviral Th1 immunity, indeed with IL-18−/−
mice the immune response following poxvirus infection is screwed
towards a Th2 cytokine proﬁle (enhanced IL-4 and IL-10), reduced
cytotoxic NK and CD8+ T cell responses and enhanced populations
of suppressive Treg cells [78]. Recent studies have demonstrated
that deletion of the MVA  IL-18BP gene can signiﬁcantly enhance
the efﬁcacy of MVA  vectored vaccines with increases in the HIV
speciﬁc CD8+ and CD4+ T cell populations following immunisation
[79].
In conclusion, our data indicate that transiently neutralising of
IL-13 activity speciﬁcally at the priming cell milieu can signiﬁ-
cantly improve the avidity of the resulting HIV speciﬁc CD8+ T cell
responses. However, the transient co-neutralisation of both IL-4
and IL-13 activity at the vaccination site is greatly beneﬁcial in the
induction of both gag-speciﬁc IgG1 and IgG2a antibody immunity,
unlike the IL-13R2 adjuvanted vaccine that only has the capac-
ity to induce IgG1 antibodies while inhibiting IgG2a. This suggests
either IL-4 cell-signalling in the absence of IL-13 delays gag-speciﬁc
antibody isotype class switching, highlighting the importance of
the IL-4R/IL-13R complex in modulating antibody immunity or IL-
13R2 signalling plays a role in modulating antibody immunity
which warrants further investigation. Our data clearly demon-
strate that the inclusion of an IL-4/IL-13 antagonist has excellent
potential to induce a more balanced immune outcome inducing
elevated high quality mucosal and systemic CD8 T cell and also B
cell immunity. This offers exciting prospects for a future HIV vac-
cine development as well as other chronic infections that which
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